Topic No. | Treatment targeted - Associated PDRM event (Medication quality category) |
---|---|
HYPERTENSION | |
Q1 | Selection of first line antihypertensives - Hypertension complications (MQ2) |
 | 1. (N) Patient with HTN and without CHD - is started on antihypertensive treatment with a first-line antihypertensive |
Q2 | Treatment to blood pressure (BP) target - Hypertension complications (MQ3) |
 | Patient aged < 75 years, who has a history of hypertension WITHOUT complications |
 | 2. (N) and BP is > 150/90 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified |
 | 3. (N) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
 | 4. (A) and BP is > 140/85 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified |
 | Patient aged ≥ 75 years, who has a history of hypertension WITHOUT complications |
 | 5. (N) and BP is > 150/90 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
 | 6. (N) and BP is > 140/85 mmHg without antihypertensive treatment - has antihypertensive treatment started |
 | 7. (A) and BP is > 150/90 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified |
 | 8. (A) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
 | Patient aged < 75 years, who has a history of hypertension WITH complications |
 | 9. (N) and BP is > 130/80 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
 | Patient aged ≥ 75 years, who has a history of hypertension WITH complications |
 | 10. (N) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
 | 11. (N) and BP is > 130/80 mmHg without antihypertensive treatment - has antihypertensive treatment intensified |
 | 12. (A) and BP is > 140/85 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified |
 | 13. (A) and BP is > 130/80 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified |
DIABETES MELLITUS | |
Q3 | Treatment to HbA1c target - Diabetes complications (MQ3) |
 | Patient with diabetes mellitus type 2, |
 | 14. (N) who has HbA1c of > 7% on < 2 oral antidiabetic drugs - has antidiabetic treatment intensified |
 | 15. (N) who has HbA1c of > 9% on < 3 oral antidiabetic drugs - has antidiabetic treatment intensified |
 | 16. (A) who has HbA1c of 6.6 to 7% without antidiabetic treatment - has antidiabetic treatment intensified |
 | 17. (A) who has HbA1c of 7.6 to 9% on < 3 oral antidiabetic drugs - has antidiabetic treatment intensified |
Q4 | Selection of first line oral antidiabetic - Diabetes complications (MQ2) |
 | 18. (N) Patient with diabetes mellitus type 2, who is overweight - is started on metformin |
Q5 | Indication for ACEI or ARB in patients with renal complications - Diabetes complications (MQ1) |
 | 19. (N) Patient with diabetes mellitus and micro-albuminuria - is prescribed an ACEI or ARB |
AT RISK OF/MANIFEST VASCULAR DISEASE | |
Q6 | Indication for statin in patients with manifest vascular disease or risk factors - Vascular events (MQ1) |
 | 20. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed a statin |
 | 21. (N) Patient with peripheral vascular disease - is prescribed a statin |
 | 22. (N) Patient aged > 40 with DM without established vascular disease - is prescribed a statin |
 | 23. (A) Patient with 10 year CVD risk > 20% without diabetes - is prescribed a statin |
Q7 | Treatment to target statin dose in patients with manifest vascular disease or risk factors - Vascular events (MQ4) |
 | 24. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed simvastatin ≥ 40 mg/d (or equivalent) |
 | 25. (N) Patient with peripheral vascular disease - is prescribed simvastatin ≥ 40 mg/d (or equivalent) |
 | 26. (N) Patient aged > 40 with DM without established vascular disease - is prescribed simvastatin ≥ 40 mg/d (or equiv.) |
 | 27. (N) Patient with 10 year CVD risk > 20% without diabetes - is prescribed simvastatin ≥ 40 mg/d (or equivalent) |
Q8 | Indication for thrombo-embolic prophylaxis in patients with CHD - Vascular events (MQ1) |
 | 28. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed any thrombo-embolic prophylaxis |
 | 29. (N) Patient with a history of peripheral vascular disease - is prescribed any thrombo-embolic prophylaxis |
 | Indication for dual antiplatelets in CHD with a history of ACS - Vascular events (MQ1) |
 | 30. (N) Patient with previous stroke/TIA - is co-prescribed aspirin and dipyridamole (unless on warfarin or clopidogrel) |
 | 31. (N) Patient with ACS 0 to 3 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin) |
 | 32. (A) Patient with ACS 4 to 9 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin) |
Q9 | Indication for beta blockers in CHD - Vascular events (MQ1) |
 | 33. (N) Patient with a history of acute coronary syndrome - is prescribed a beta blocker |
 | 34. (N) Patient with stable angina without a history of acute coronary syndrome - is prescribed a beta blocker |
Q10 | Indication for ACEI or ARB in CHD - Vascular events (MQ1) |
 | 35. (N) Patient with a history of acute coronary syndrome - is prescribed an ACEI or ARB |
 | 36. (A) Patient with stable angina without a history of acute coronary syndrome - is prescribed an ACEI or ARB |
CHRONIC HEART FAILURE | |
Q11 | Indication for ACEI or ARB in CHF - Heart failure progression (MQ1) |
 | 37. (N) Patient with CHF - is prescribed an ACE or ARB |
Q12 | Indication for Beta blocker in CHF - Heart failure progression (MQ1) |
 | 38. (N) Patient with CHF - is prescribed a beta blocker |
 | Selection of licensed beta blocker in CHF - Heart failure progression (MQ2) |
 | 39. (A) Patient with CHF and treated with a BB - is prescribed a BB licensed for CHF |
Q13 | Treatment to target dose (ACEI and ARB) in CHF - Heart failure progression (MQ4) |
 | 40. (N) Patient with CHF and treated with an ACEI or ARB - has achieved the recommended target dose |
Q13 | Treatment to target dose (beta blocker) - CHF- Prevention of heart failure progression (MQ4) |
 | 41. (N) Patient with CHF and treated with a beta blocker - has achieved the recommended target dose |
ATRIAL FIBRILLATION | |
Q14 | Indication for thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ1) |
 | 42. (N) Patient with atrial fibrillation and a CHADS2 score of 0 or 1 - is prescribed thrombo-embolic prophylaxis |
 | 43. (N) Patient with atrial fibrillation and a CHADS2 score of 2 - is prescribed thrombo-embolic prophylaxis |
 | 44. (N) Patient with atrial fibrillation and a CHADS2 score ≥ 3 - is prescribed thrombo-embolic prophylaxis |
Q15 | Selection of thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ2) |
 | 45. (N) Patient with AF and a CHADS2 score ≥ 3 treated with an antithrombotic - is prescribed an oral anticoagulant |
ASTHMA | |
Q16 | Indication for inhaled corticosteroids in asthma - Asthma exacerbation (MQ1) |
 | Patient aged > 4 with asthma but without COPD and |
 | 46. (N) is treated with a step 3 drug* - is also prescribed an inhaled corticosteroid |
 | 47. (N) has received oral prednisolone in last 12 weeks - is also prescribed an inhaled corticosteroid |
 | 48. (N) has received ≥ 3 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid |
 | 49. (A) has received 2 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid |
 | * long acting beta agonist, leukotriene receptor antagonist or theophylline |
OSTEOPOROSIS | |
Q17 | Indication for bone protecting agents in patients with osteoporosis - Fractures (MQ1) |
 | 50. (N) Female patient with osteoporosis who had a vertebral fracture - is prescribed a bone protecting agent* |
 | * a bisphosphonate, strontium ranelate, raloxifene or teriparatide |
Q18 | Indication for Calcium/vitamin D in patients at risk of osteoporosis - Fractures (MQ1) |
 | 51. (N) Female patient aged ≥ 80 who is housebound - is prescribed calcium and vitamin D |
 | 52. (N) Female patient aged ≥ 80 who lives in a nursing home/residential care - is prescribed calcium and vitamin D |